Amyotrophic lateral sclerosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Tooba Kashif (talk | contribs) |
Tooba Kashif (talk | contribs) |
||
(One intermediate revision by the same user not shown) | |||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There are no diagnostic laboratory findings associated with [[Amyotrophic lateral sclerosis]]. | There are no diagnostic laboratory findings associated with [[Amyotrophic lateral sclerosis]], but workup is done to rule out other neurodegenerative diseases. | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
*Typical labs drawn in patients with ALS are: | *Typical labs drawn in patients with ALS are: | ||
**[[Erythrocyte sedimentation rate]] | **[[Erythrocyte sedimentation rate]] | ||
**[[Complete blood count]] | |||
**[[Creatine kinase]] | |||
** [[Creatine]] | |||
**Serum and [[urine]] protein [[electrophoresis]] | **Serum and [[urine]] protein [[electrophoresis]] | ||
**[[Thyroid function tests]] | **[[Thyroid function tests]] | ||
** | **[[Complete metabolic panel]] | ||
**[[CSF analysis]] | **[[CSF analysis]] | ||
*Heavy metal screening is indicated in patients with a potential history of exposure.<ref name="pmid26629397">{{cite journal| author=Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF et al.| title=A comprehensive review of amyotrophic lateral sclerosis. | journal=Surg Neurol Int | year= 2015 | volume= 6 | issue= | pages= 171 | pmid=26629397 | doi=10.4103/2152-7806.169561 | pmc=4653353 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26629397 }} </ref><ref name="pmid21989247">{{cite journal| author=Hardiman O, van den Berg LH, Kiernan MC| title=Clinical diagnosis and management of amyotrophic lateral sclerosis. | journal=Nat Rev Neurol | year= 2011 | volume= 7 | issue= 11 | pages= 639-49 | pmid=21989247 | doi=10.1038/nrneurol.2011.153 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21989247 }} </ref> | *Heavy metal screening is indicated in patients with a potential history of exposure.<ref name="pmid26629397">{{cite journal| author=Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF et al.| title=A comprehensive review of amyotrophic lateral sclerosis. | journal=Surg Neurol Int | year= 2015 | volume= 6 | issue= | pages= 171 | pmid=26629397 | doi=10.4103/2152-7806.169561 | pmc=4653353 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26629397 }} </ref><ref name="pmid21989247">{{cite journal| author=Hardiman O, van den Berg LH, Kiernan MC| title=Clinical diagnosis and management of amyotrophic lateral sclerosis. | journal=Nat Rev Neurol | year= 2011 | volume= 7 | issue= 11 | pages= 639-49 | pmid=21989247 | doi=10.1038/nrneurol.2011.153 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21989247 }} </ref> | ||
Line 22: | Line 25: | ||
**[[Hypochloremia]], increased [[bicarbonate]] (related to advanced [[respiratory]] compromise) | **[[Hypochloremia]], increased [[bicarbonate]] (related to advanced [[respiratory]] compromise) | ||
**Elevated [[CSF]] [[protein]] (uncommonly more than 100 mg/dl) | **Elevated [[CSF]] [[protein]] (uncommonly more than 100 mg/dl) | ||
==References== | ==References== |
Latest revision as of 20:44, 15 September 2021
Amyotrophic lateral sclerosis Microchapters |
Differentiating Amyotrophic lateral sclerosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Amyotrophic lateral sclerosis laboratory findings On the Web |
American Roentgen Ray Society Images of Amyotrophic lateral sclerosis laboratory findings |
Amyotrophic lateral sclerosis laboratory findings in the news |
Risk calculators and risk factors for Amyotrophic lateral sclerosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
There are no diagnostic laboratory findings associated with Amyotrophic lateral sclerosis, but workup is done to rule out other neurodegenerative diseases.
Laboratory Findings
- Typical labs drawn in patients with ALS are:
- Heavy metal screening is indicated in patients with a potential history of exposure.[1][2]
- In Ashkenazi Jews, B-hexaminidase subunits alpha and beta activity should be tested because deficiency in this enzyme mimics ALS, but in reality is the rare autosomal recessive genetic disorder, Tay-Sachs.[1][2]
- Other clinical laboratory tests that may be abnormal in otherwise typical case of ALS include:[3][4]
- Muscle enzymes (serum creatine kinase [unusual above ten times upper limit of normal, ALT, AST, LDH)
- Serum creatinine (related to loss of skeletal muscle mass)
- Hypochloremia, increased bicarbonate (related to advanced respiratory compromise)
- Elevated CSF protein (uncommonly more than 100 mg/dl)
References
- ↑ 1.0 1.1 Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF; et al. (2015). "A comprehensive review of amyotrophic lateral sclerosis". Surg Neurol Int. 6: 171. doi:10.4103/2152-7806.169561. PMC 4653353. PMID 26629397.
- ↑ 2.0 2.1 Hardiman O, van den Berg LH, Kiernan MC (2011). "Clinical diagnosis and management of amyotrophic lateral sclerosis". Nat Rev Neurol. 7 (11): 639–49. doi:10.1038/nrneurol.2011.153. PMID 21989247.
- ↑ Wijesekera LC, Leigh PN (2009). "Amyotrophic lateral sclerosis". Orphanet J Rare Dis. 4: 3. doi:10.1186/1750-1172-4-3. PMC 2656493. PMID 19192301.
- ↑ Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000). "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotroph Lateral Scler Other Motor Neuron Disord. 1 (5): 293–9. PMID 11464847.